SS-31 (Elamipretide) Peptide Research Guide: Mitochondrial Cardiolipin & Longevity

Research guide to SS-31 (Elamipretide) — the Szeto-Schiller mitochondria-targeting peptide that stabilizes cardiolipin in the inner mitochondrial membrane, with Phase 2/3 heart failure trial data, dosing, and longevity applications.

TL;DR

• SS-31 targets cardiolipin in the inner mitochondrial membrane — a unique mechanism no other supplement achieves
• Reduces mitochondrial ROS while improving electron transport chain efficiency and ATP production
• Phase 2/3 human trials in heart failure (HFpEF) and mitochondrial myopathy show functional benefits
• Research doses: 0.5-5mg/day SubQ; reconstitute in bacteriostatic water at 1mg/mL

Disclaimer: For educational and research purposes only — not medical advice.

SS-31 (Szeto-Schiller peptide 31), now in clinical development as Elamipretide, is a tetrapeptide developed by Dr. Hazel Szeto at Cornell University. It represents the most advanced example of a mitochondria-targeted therapeutic peptide, with a mechanism of action focused on the inner mitochondrial membrane rather than the cytoplasm or nucleus.

Unlike antioxidant supplements that scavenge reactive oxygen species (ROS) non-selectively, SS-31 acts at the source of mitochondrial ROS production — the electron transport chain (ETC) — by stabilizing the lipid environment in which ETC complexes are embedded.

Cardiolipin: The Critical Target

Cardiolipin is a unique phospholipid found almost exclusively in the inner mitochondrial membrane (IMM). It serves as a structural anchor for ETC complexes (I, III, IV) and Complex V (ATP synthase), and is essential for maintaining the optimal electrochemical gradient for ATP synthesis.

With aging, oxidative stress, and disease, cardiolipin undergoes oxidation — disrupting ETC complex organization, causing electron leakage to oxygen (forming superoxide), and reducing ATP synthesis efficiency. This cardiolipin oxidation is increasingly recognized as a central driver of mitochondrial dysfunction in aging and age-related diseases.

SS-31 concentrates in the IMM (driven by the mitochondrial membrane potential) and directly binds cardiolipin through ionic interactions. This binding:

1. Prevents cardiolipin oxidation
2. Stabilizes ETC complex interactions
3. Reduces electron leak → less ROS
4. Restores ATP synthesis rate

Animal Research Highlights

Animal studies across multiple models demonstrate SS-31's biological activity:

The age-reversal data in mice — showing functional improvements in already-aged animals — is particularly relevant to longevity research, suggesting SS-31 can restore mitochondrial function even after significant age-related decline has occurred.

Human Clinical Trial Data

HOPEFUL-1 (HFpEF): A Phase 2 randomized controlled trial testing IV SS-31 (Elamipretide) in patients with heart failure with preserved ejection fraction. The trial showed significant improvements in 6-minute walk distance (primary endpoint), left atrial volume index, and patient-reported quality of life metrics compared to placebo.

MMPOWER-3 (Barth Syndrome): Barth syndrome is a rare mitochondrial cardiomyopathy caused by cardiolipin remodeling enzyme deficiency — making it an ideal proof-of-concept condition for a cardiolipin-targeting therapy. Phase 3 trials demonstrated improved muscle strength and functional capacity.

These results represent the most compelling human evidence for any mitochondria-targeted peptide and provide mechanistic validation for SS-31's cardiolipin hypothesis.

Reconstitution and Dosing

Standard SS-31 research preparation:

• Typical vial: 5mg lyophilized powder
• Reconstitution: Add 5mL bacteriostatic water → 1mg/mL solution
• Storage: Reconstituted at 4°C for up to 2 weeks; lyophilized at -20°C for 2+ years
• Administration: Subcutaneous injection, rotating sites

Research dose calculations:

• Conservative: 0.5mg/day (0.5mL at 1mg/mL)
• Moderate: 2mg/day (2mL at 1mg/mL, split AM/PM)
• Animal-equivalent: ~0.5-1mg/kg/day (70kg subject = 35-70mg — well above typical research use)

Most longevity researchers use 1-5mg/day as a reasonable range based on scaling from animal research with safety considerations.

Comparison with Other Mitochondrial Peptides

SS-31 is uniquely positioned as the only compound with a specific cardiolipin-binding mechanism and Phase 2/3 trial data.

Frequently Asked Questions

Q: Is SS-31 the same as MitoQ or CoQ10? A: No — SS-31, MitoQ, and CoQ10 all target mitochondria but through different mechanisms. CoQ10 is an electron carrier in the ETC. MitoQ is a TPP-conjugated CoQ10 that concentrates in mitochondria. SS-31 specifically binds cardiolipin and stabilizes ETC complexes — a structurally distinct and mechanistically unique approach.

Q: Can SS-31 be combined with other longevity compounds? A: Yes — SS-31 complements the mitochondrial peptide trio (MOTS-c for AMPK/metabolic function, Humanin for cytoprotection) and works alongside NAD+ precursors (NMN/NR for sirtuin and PARP support), CoQ10, and Epitalon (telomere-focused). There are no known negative interactions between these compounds.

Use the Reconstitution Calculator → /calculators/reconstitution

For educational and research purposes only. Not medical advice.

Disclaimer: For educational and research purposes only. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendation. All compounds discussed are research chemicals or investigational compounds unless explicitly noted otherwise. Consult a qualified healthcare professional before making any health-related decisions. Researchers must comply with all applicable laws and regulations in their jurisdiction.

Frequently Asked Questions